Search

Your search keyword '"Senter L."' showing total 291 results

Search Constraints

Start Over You searched for: Author "Senter L." Remove constraint Author: "Senter L."
291 results on '"Senter L."'

Search Results

1. Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis

2. Erratum: Correction to: Survival from breast cancer in women with a BRCA2 mutation by treatment (British journal of cancer (2021) 124 9 (1524-1532))

4. The risks of cancer in older women with BRCA pathogenic variants: How far have we come?

5. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation

8. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers

9. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

10. Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium

11. Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium

12. The Risks of Breast and Ovarian Cancer Associated with the Ashkenazi Jewish Founder Allele BRCA2 6174delT

13. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: a Reappraisal

14. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers

15. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers

16. Survival from breast cancer in women with a BRCA2 mutation by treatment.

17. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.

18. Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

19. Survival from breast cancer in women with a BRCA2 mutation by treatment

20. Survival from breast cancer in women with a BRCA2 mutation by treatment

21. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers

23. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

24. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

25. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

26. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

27. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness.

28. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

29. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.

30. GWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer

31. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

32. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

33. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

34. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation

37. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

39. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.

40. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

41. Cancer Risks for PMS2-Associated Lynch Syndrome (vol 29, pg 2961, 2018)

42. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers

43. An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome.

44. The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers

45. Does using hormonal therapy after risk reducing salpingo-oophorectomy increase the incidence of malignancy in women with high risk genetic predisposition to cancer?

47. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

48. Cancer Risks for PMS2-Associated Lynch Syndrome

49. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

Catalog

Books, media, physical & digital resources